Andreas Busch, Ph.D., is a distinguished figure in the field of biopharmaceutical innovation, currently serving as the Chief Innovation Officer at Absci Corp. Dr. Busch brings a wealth of experience from his extensive career in drug discovery and development. Prior to joining Absci, he held pivotal roles at several leading pharmaceutical companies, including Bayer and Merck, where he was instrumental in advancing numerous drug candidates from discovery to clinical trials. His academic credentials are equally impressive, with a Ph.D. in biochemistry from the University of Heidelberg, followed by postdoctoral research at the Max Planck Institute. At Absci Corp, Dr. Busch is at the forefront of leveraging artificial intelligence and machine learning to revolutionize the drug discovery process. His role as Chief Innovation Officer involves steering the company's strategic direction in integrating cutting-edge technologies to accelerate the development of novel therapeutics. Under his leadership, Absci has made significant strides in enhancing its AI-driven drug discovery platform, which has the potential to drastically reduce the time and cost associated with bringing new drugs to market. Dr. Busch's visionary approach has been crucial in positioning Absci as a leader in the burgeoning field of AI-driven biopharma. Dr. Busch's contributions to the scientific community extend beyond his corporate roles. He is a prolific author, with numerous publications in peer-reviewed journals, and a frequent speaker at international conferences, where he shares insights on the future of drug discovery. His commitment to innovation and excellence has earned him several accolades, including the prestigious Innovation Award from the International Society for Pharmaceutical Engineering. As Absci continues to grow and push the boundaries of what's possible in biopharmaceuticals, Dr. Busch's leadership and expertise remain invaluable assets to the company and the industry at large.